EMA to Meet Roadmap Goals Through Adaptive Licensing, Other Initiatives

The European Medicines Agency (EMA) is considering three new regulatory initiatives to improve drug safety and access, including adaptive licensing — authorizing drugs sooner but with greater initial limitations.
International Pharmaceutical Regulatory Monitor